JP2017502075A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017502075A5 JP2017502075A5 JP2016550953A JP2016550953A JP2017502075A5 JP 2017502075 A5 JP2017502075 A5 JP 2017502075A5 JP 2016550953 A JP2016550953 A JP 2016550953A JP 2016550953 A JP2016550953 A JP 2016550953A JP 2017502075 A5 JP2017502075 A5 JP 2017502075A5
- Authority
- JP
- Japan
- Prior art keywords
- subject
- months
- nucleotide stretch
- antagonist
- central
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000002773 nucleotide Substances 0.000 claims 87
- 125000003729 nucleotide group Chemical group 0.000 claims 87
- 239000005557 antagonist Substances 0.000 claims 38
- 102100021943 C-C motif chemokine 2 Human genes 0.000 claims 33
- 150000007523 nucleic acids Chemical group 0.000 claims 27
- 108020004707 nucleic acids Proteins 0.000 claims 21
- 102000039446 nucleic acids Human genes 0.000 claims 21
- 101710155857 C-C motif chemokine 2 Proteins 0.000 claims 17
- 201000001474 proteinuria Diseases 0.000 claims 13
- 230000024924 glomerular filtration Effects 0.000 claims 10
- 238000000034 method Methods 0.000 claims 9
- 206010012601 diabetes mellitus Diseases 0.000 claims 5
- 210000003734 kidney Anatomy 0.000 claims 3
- 230000004048 modification Effects 0.000 claims 3
- 238000012986 modification Methods 0.000 claims 3
- 239000005541 ACE inhibitor Substances 0.000 claims 2
- 101710129690 Angiotensin-converting enzyme inhibitor Proteins 0.000 claims 2
- 101710086378 Bradykinin-potentiating and C-type natriuretic peptides Proteins 0.000 claims 2
- 206010020772 Hypertension Diseases 0.000 claims 2
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 2
- 102000004005 Prostaglandin-endoperoxide synthases Human genes 0.000 claims 2
- 108090000459 Prostaglandin-endoperoxide synthases Proteins 0.000 claims 2
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 claims 2
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 238000011065 in-situ storage Methods 0.000 claims 2
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims 2
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims 2
- 150000003431 steroids Chemical class 0.000 claims 2
- 238000002560 therapeutic procedure Methods 0.000 claims 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 2
- ZOBPZXTWZATXDG-UHFFFAOYSA-N 1,3-thiazolidine-2,4-dione Chemical compound O=C1CSC(=O)N1 ZOBPZXTWZATXDG-UHFFFAOYSA-N 0.000 claims 1
- XGWFJBFNAQHLEF-UHFFFAOYSA-N 9-anthroic acid Chemical compound C1=CC=C2C(C(=O)O)=C(C=CC=C3)C3=CC2=C1 XGWFJBFNAQHLEF-UHFFFAOYSA-N 0.000 claims 1
- 208000023769 AA amyloidosis Diseases 0.000 claims 1
- 208000023761 AL amyloidosis Diseases 0.000 claims 1
- 208000009304 Acute Kidney Injury Diseases 0.000 claims 1
- 108010088751 Albumins Proteins 0.000 claims 1
- 102000009027 Albumins Human genes 0.000 claims 1
- UXOWGYHJODZGMF-QORCZRPOSA-N Aliskiren Chemical compound COCCCOC1=CC(C[C@@H](C[C@H](N)[C@@H](O)C[C@@H](C(C)C)C(=O)NCC(C)(C)C(N)=O)C(C)C)=CC=C1OC UXOWGYHJODZGMF-QORCZRPOSA-N 0.000 claims 1
- 208000024985 Alport syndrome Diseases 0.000 claims 1
- 102000015427 Angiotensins Human genes 0.000 claims 1
- 108010064733 Angiotensins Proteins 0.000 claims 1
- 108091023037 Aptamer Proteins 0.000 claims 1
- 208000024172 Cardiovascular disease Diseases 0.000 claims 1
- 102100024502 Ceramide glucosyltransferase Human genes 0.000 claims 1
- 208000032928 Dyslipidaemia Diseases 0.000 claims 1
- 108060006698 EGF receptor Proteins 0.000 claims 1
- 208000024720 Fabry Disease Diseases 0.000 claims 1
- 206010018364 Glomerulonephritis Diseases 0.000 claims 1
- 206010018372 Glomerulonephritis membranous Diseases 0.000 claims 1
- 101000981050 Homo sapiens Ceramide glucosyltransferase Proteins 0.000 claims 1
- 208000010159 IgA glomerulonephritis Diseases 0.000 claims 1
- 206010021263 IgA nephropathy Diseases 0.000 claims 1
- 208000005531 Immunoglobulin Light-chain Amyloidosis Diseases 0.000 claims 1
- 208000005230 Leg Ulcer Diseases 0.000 claims 1
- 208000017170 Lipid metabolism disease Diseases 0.000 claims 1
- 208000005777 Lupus Nephritis Diseases 0.000 claims 1
- 241001465754 Metazoa Species 0.000 claims 1
- 208000034578 Multiple myelomas Diseases 0.000 claims 1
- 208000000175 Nail-Patella Syndrome Diseases 0.000 claims 1
- 206010029164 Nephrotic syndrome Diseases 0.000 claims 1
- 206010030113 Oedema Diseases 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 206010036673 Primary amyloidosis Diseases 0.000 claims 1
- 206010037549 Purpura Diseases 0.000 claims 1
- 241001672981 Purpura Species 0.000 claims 1
- 208000033626 Renal failure acute Diseases 0.000 claims 1
- 206010039811 Secondary amyloidosis Diseases 0.000 claims 1
- 229940123464 Thiazolidinedione Drugs 0.000 claims 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 1
- 206010047115 Vasculitis Diseases 0.000 claims 1
- 201000011040 acute kidney failure Diseases 0.000 claims 1
- 229960004601 aliskiren Drugs 0.000 claims 1
- 230000036772 blood pressure Effects 0.000 claims 1
- 230000007211 cardiovascular event Effects 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 229940109239 creatinine Drugs 0.000 claims 1
- 201000003278 cryoglobulinemia Diseases 0.000 claims 1
- 238000000502 dialysis Methods 0.000 claims 1
- 239000002934 diuretic Substances 0.000 claims 1
- 229940030606 diuretics Drugs 0.000 claims 1
- 201000005206 focal segmental glomerulosclerosis Diseases 0.000 claims 1
- 231100000854 focal segmental glomerulosclerosis Toxicity 0.000 claims 1
- 201000011200 hepatorenal syndrome Diseases 0.000 claims 1
- 208000003215 hereditary nephritis Diseases 0.000 claims 1
- 201000001421 hyperglycemia Diseases 0.000 claims 1
- 239000003018 immunosuppressive agent Substances 0.000 claims 1
- 229940124589 immunosuppressive drug Drugs 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 208000017169 kidney disease Diseases 0.000 claims 1
- 201000008350 membranous glomerulonephritis Diseases 0.000 claims 1
- 231100000855 membranous nephropathy Toxicity 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 201000008158 rapidly progressive glomerulonephritis Diseases 0.000 claims 1
- 239000003087 receptor blocking agent Substances 0.000 claims 1
- 230000000699 topical effect Effects 0.000 claims 1
- 230000002485 urinary effect Effects 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13005191 | 2013-11-04 | ||
| EP13005191.5 | 2013-11-04 | ||
| EP14001242.8 | 2014-04-03 | ||
| EP14001242 | 2014-04-03 | ||
| PCT/EP2014/002945 WO2015062743A1 (en) | 2013-11-04 | 2014-11-04 | Means and methods for the treatment of nephropathy |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019177412A Division JP2020059698A (ja) | 2013-11-04 | 2019-09-27 | 腎障害治療の手段および方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017502075A JP2017502075A (ja) | 2017-01-19 |
| JP2017502075A5 true JP2017502075A5 (https=) | 2017-12-14 |
Family
ID=51870980
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016550953A Pending JP2017502075A (ja) | 2013-11-04 | 2014-11-04 | 腎障害治療の手段および方法 |
| JP2019177412A Pending JP2020059698A (ja) | 2013-11-04 | 2019-09-27 | 腎障害治療の手段および方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019177412A Pending JP2020059698A (ja) | 2013-11-04 | 2019-09-27 | 腎障害治療の手段および方法 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US20170233737A1 (https=) |
| EP (1) | EP3065744B1 (https=) |
| JP (2) | JP2017502075A (https=) |
| WO (1) | WO2015062743A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2765737C2 (ru) | 2016-11-23 | 2022-02-02 | Хемоцентрикс, Инк. | Способ лечения фокально-сегментарного гломерулосклероза |
| RU2020113612A (ru) | 2017-10-11 | 2021-11-12 | Хемоцентрикс, Инк. | Лечение фокально-сегментарного гломерулосклероза антагонистами ccr2 |
| CN116356015A (zh) * | 2023-04-28 | 2023-06-30 | 皖南医学院第一附属医院（皖南医学院弋矶山医院） | Nap-3、lft及ccl2在糖尿病肾病发病风险预测和诊断的应用 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2259800T3 (es) | 1990-06-11 | 2006-10-16 | Gilead Sciences, Inc. | Procedimientos de uso de ligandos de acido nucleico. |
| US6011020A (en) | 1990-06-11 | 2000-01-04 | Nexstar Pharmaceuticals, Inc. | Nucleic acid ligand complexes |
| DE59708838D1 (de) | 1996-08-30 | 2003-01-09 | Jens Peter Fuerste | Spiegelselektion und spiegelevolution von nucleinsäuren |
| DE19742706B4 (de) | 1997-09-26 | 2013-07-25 | Pieris Proteolab Ag | Lipocalinmuteine |
| US6395029B1 (en) | 1999-01-19 | 2002-05-28 | The Children's Hospital Of Philadelphia | Sustained delivery of polyionic bioactive agents |
| US6652886B2 (en) | 2001-02-16 | 2003-11-25 | Expression Genetics | Biodegradable cationic copolymers of poly (alkylenimine) and poly (ethylene glycol) for the delivery of bioactive agents |
| EP1306382A1 (de) | 2001-10-26 | 2003-05-02 | Noxxon Pharma AG | Modifizierte L-Nukleinsäure |
| ATE469164T1 (de) | 2001-10-26 | 2010-06-15 | Noxxon Pharma Ag | Modifizierte l-nukleinsäure |
| WO2003070823A2 (en) | 2002-02-20 | 2003-08-28 | The General Hospital Corporation | Conjugates comprising a biodegradable polymer and uses therefor |
| NZ542687A (en) | 2003-04-13 | 2010-02-26 | Enzon Pharmaceuticals Inc | Polymeric oligonucleotide prodrugs |
| GB0314472D0 (en) | 2003-06-20 | 2003-07-23 | Warwick Effect Polymers Ltd | Polymer |
| CA2555467C (en) | 2004-02-09 | 2012-10-09 | Noxxon Pharma Ag | Process for the production of conjugates from polysaccharides and polynucleotides |
| CA2940803A1 (en) | 2004-03-23 | 2005-10-27 | Ascendis Pharma Gmbh | Prodrug linker |
| JP5107716B2 (ja) | 2004-11-05 | 2012-12-26 | ザ・チルドレンズ・ホスピタル・オブ・フィラデルフィア | 分子治療用生分解性リンカー |
| DK2135949T3 (da) | 2006-02-14 | 2013-02-04 | Noxxon Pharma Ag | MCP-1-bindende nukleinsyrer |
| MX2009002859A (es) | 2006-09-15 | 2009-03-30 | Enzon Pharmaceuticals Inc | Enlazadores biodegradables a base de ester impedido para suministro de oligonucleotidos. |
| CN101878305A (zh) * | 2007-11-30 | 2010-11-03 | 诺松制药股份公司 | 结合mcp-1的核酸及其用途 |
| WO2012025251A1 (en) * | 2010-08-27 | 2012-03-01 | Noxxon Pharma Ag | Nucleic acids for treatment of chronic complications of diabetes |
-
2014
- 2014-11-04 EP EP14795956.3A patent/EP3065744B1/en active Active
- 2014-11-04 WO PCT/EP2014/002945 patent/WO2015062743A1/en not_active Ceased
- 2014-11-04 JP JP2016550953A patent/JP2017502075A/ja active Pending
- 2014-11-04 US US15/034,036 patent/US20170233737A1/en not_active Abandoned
-
2019
- 2019-09-27 JP JP2019177412A patent/JP2020059698A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Kobori et al. | AT1 receptor mediated augmentation of intrarenal angiotensinogen in angiotensin II-dependent hypertension | |
| Yang et al. | Ischemia-reperfusion induces renal tubule pyroptosis via the CHOP-caspase-11 pathway | |
| JP2011184466A5 (https=) | ||
| JP2010507594A5 (https=) | ||
| JP2011522832A5 (https=) | ||
| JP2020503362A5 (https=) | ||
| JP2009540018A5 (https=) | ||
| WO2008149146A3 (en) | Polypeptides, antibody variable domains and antagonists | |
| EP2746291A3 (en) | Pulmonary formulation comprising an immunoglobulin single variable domain which binds to TNFR1 | |
| JP2017502075A5 (https=) | ||
| JP2011507891A5 (https=) | ||
| JP2019512532A5 (https=) | ||
| WO2012162394A3 (en) | Compositions and methods for treating renal disease | |
| JP2017113019A5 (https=) | ||
| JP2009522339A5 (https=) | ||
| NZ753546A (en) | Methods of treating alport syndrome using bardoxolone methyl or analogs thereof | |
| JP2018529779A5 (https=) | ||
| JP2020506715A5 (https=) | ||
| Jackson et al. | Bariatric surgery and microvascular complications of type 2 diabetes mellitus | |
| JP2009508822A5 (https=) | ||
| JP2018526443A5 (https=) | ||
| Bardin | Canakinumab for the patient with difficult-to-treat gouty arthritis: review of the clinical evidence | |
| Kinoshita et al. | Angiotensin II type I receptor blockade suppresses glomerular renin-angiotensin system activation, oxidative stress, and progressive glomerular injury in rat anti-glomerular basement membrane glomerulonephritis | |
| JP2017520562A5 (https=) | ||
| Trachtman et al. | Sparsentan. dual angiotensin II AT1 receptor blocker and endothelin ETA receptor antagonist, treatment of focal segmental glomerulosclerosis, treatment of IgA nephropathy |